Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine/glycopyrrolate for reversal of neuromuscular block after laparoscopic gynaecological surgery
ACTRN12611000789965Phase 4Terminated
- Sponsor
- King Edward Memorial Hospital
- Start
- Oct 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex, neostigmine, glycopyrronium and rocuronium in Postoperative residual curarization (PORC) (2 arms), sponsored by King Edward Memorial Hospital. Primary endpoint: Cumulative incidence and severity of post-operative nausea and vomiting. Started Oct 2011; status: terminated.
02
Drugs
Sugammadexneostigmineglycopyrroniumrocuronium
03
Conditions
Postoperative residual curarization (PORC)
Beyond the preview
Go deeper on ACTRN12611000789965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000789965.